In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands

The synthesis and in vitro anticancer activity of dihalogenido(eta(6)-p-cymene)(3,5,6-bicyclophosphite-alpha-D- glucofuranoside)ruthenium(II) complexes are described. The compounds were characterized by NMR spectroscopy and ESI mass spectrometry, and the molecular structures of dichlorido-, dibromido- and diiodido(eta(6)-p-cymene)(3,5,6-bicyclophosphite-1,2-O- isopropylidene-alpha-D-glucofuranoside)-ruthenium(II) were determined by X-ray diffraction analysis. The complexes were shown to undergo aquation of the first halido ligand in aqueous solution, followed by hydrolysis of a P-O bond of the phosphite ligand, and finally formation of dinuclear species. The hydrolysis mechanism was confirmed by DFT calculations. The aquation of the complexes was markedly suppressed in 100 mm NaCl solution, and notably only very slow hydrolysis of the P-O bond was observed. The complexes showed affinity towards albumin and transferrin and monoadduct formation with 9-ethylguanine. In vitro studies revealed that the 3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-alpha-D-glucofura- noside complex is the most cytotoxic compound in human cancer cell lines (IC50 values from 30 to 300 mu m depending on the cell line).